Conditions: Non-small Cell Lung Cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 50
Healthy volunteers: no

Brief summary:
This study assessed the efficacy and safety of Avastin in combination with docetaxel and cisplatin as first-line treatment of patients with metastatic or locally advanced non-small cell lung cancer. Patients received Avastin 15 mg/kg intravenously (IV), docetaxel 75 mg/m\^2, and cisplatin 75 mg/m\^2 on Day 1 of each 3-week cycle for a maximum of 6 cycles.

Detailed description:

Arms:
arm 1: Participants received bevacizumab 15 mg/kg intravenously (IV) followed by docetaxel 75 mg/kg IV in combination with cisplatin 75 mg/m\^2 IV on Day 1 of each 3-week cycle for a maximum of 6 cycles. After completing the 6 cycles of combined chemotherapy, participants received bevacizumab 15 mg/kg IV until disease progression, unacceptable toxicity, or withdrawal of consent.

Interventions: intervention 1: Bevacizumab intervention 2: Cisplatin intervention 3: Docetaxel
Intervention descriptions: intervention 1: Bevacizumab was supplied as a sterile liquid in glass vials. intervention 2: Bevacizumab was supplied as a sterile liquid in glass vials. intervention 3: Bevacizumab was supplied as a sterile liquid in glass vials.

Protocol document: